On October 5, 2015 Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis technology platform, reported the company will host a special briefing conference call focused on the current clinical research landscape in metastatic renal cell carcinoma (mRCC) (Press release, Argos Therapeutics, OCT 5, 2015, View Source [SID:1234507642]). The briefing will feature Dr. Charles Drake, co-director of the division of immunology, professor of medical oncology, immunology, and urology at the Johns Hopkins Sidney Kimmel Cancer Center. The conference call is scheduled for Wednesday, October 7, 2015 at 4:30pm ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the briefing, Dr. Drake will review data presented during the 40th Congress of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) held September 25-29, 2015 in Vienna, Austria, and will discuss the implications for clinical research in mRCC moving forward.
In addition to the presentation by Dr. Drake, Dr. Charles Nicolette, Argos’ chief scientific officer and vice president of research and development, will also provide an update on the company’s lead product candidate, AGS-003, and the pivotal ADAPT phase 3 clinical trial for the treatment of mRCC.
To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 55129797. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.argostherapeutics.com. The archived webcast will remain available on the Company’s website for fourteen (14) days following the call.
About the Arcelis Technology Platform
Arcelis is a fully individualized immunotherapy technology that captures mutated and variant antigens that are specific to each patient’s disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis process uses only a small tumor or blood sample and the patient’s own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process isolates RNA from the patient’s disease sample to program the optimized dendritic cells to present disease specific antigens to circulating T-cells in vivo. The antigen-loaded dendritic cells are also activated with CD40L, a critical co-stimulatory factor, then combined with the patient’s plasma and administered via intradermal injection, resulting in the activation, differentiation and proliferation of memory and tumor-specific killer T-cells. The high-yield process enables multiple doses to be created from a single patient cell collection.